SEC Tracker
Get the app

Nu-Med Plus NUMD

Nu-Med Plus FY 2021: net loss $830K; diluted EPS −$0.01

Form
10-K/A
Filed
Period
Importance
Routine
Document
10-K/A

Key figures from this report

These are the numbers Nu-Med Plus reported for the year ended Dec 31, 2021, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Net income−$830KAgainst −$2.0M in FY 202010-K/A income statement, on EDGAR
  2. Diluted EPS−$0.01Against −$0.04 in FY 202010-K/A income statement, on EDGAR
  3. Cash and cash equivalents$12K−94% from $189K in FY 202010-K balance sheet, on EDGAR
  4. Cash from operations−$207KAgainst −$415K in FY 202010-K/A cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when Nu-Med Plus files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 3841 and related industry codes: the same peer list as the financial tables.

  1. STRATA Skin Sciences SSKN public float $4M, Jun 30, 2025
  2. ENDRA Life Sciences NDRA public float $3M, Jun 30, 2025
  3. Catheter Precision VJET public float $4M, Jun 30, 2025
  4. Global Innovative Platforms GIPL public float $3M, Sep 30, 2025
  5. Interpace Biosciences IDXG public float $3M, Jun 30, 2025